ClinicalTrials.gg
CompletedNCT06336356Updated Dec 17, 2025Results posted

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

A Phase 2 interventional study of Baxdrostat and Placebo in Uncontrolled Hypertension, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
12th of 18
48 · median 197
Started
2024
with 3 others
Phase 2
5 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 12th largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 2, and was the 14th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.

Read the detailed description

This is a placebo-controlled study to evaluate cortisol reserve after ACTH stimulation test following treatment with 2 milligrams (mg) baxdrostat versus placebo.

The study consists of 3 period:

  • 4-week screening period.
  • An 8-week double-blind treatment period.
  • A safety follow-up 2 weeks after last dose.

Participants will be randomized in a 2:1 ratio to one of 2 treatment arms:

  1. Baxdrostat
  2. Placebo

Participants will receive either baxdrostat or placebo.

The overall study duration will be up to 16 weeks.

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

Keywords

  • Adrenocorticotropic hormone stimulation
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with mean seated systolic blood pressure (SBP) on automated office blood pressure measurement (AOBPM) greater than equal to (>=) 130 millimeter of mercury (mmHg) and less than (\<) 170 mmHg at screening.
  • Participants with mean seated SBP on AOBPM of >=130 mmHg and \< 170 mmHg at randomization.
  • Participants must have a stable regimen of >=1 antihypertensive medication (at least one should be a diuretic), for at least 4 weeks prior to screening.
  • Participants must have an estimated (eGFR) >=45 milliliter per minute (mL/min)/1.73-meter square (m\^²) at screening.
  • Participants must have a serum potassium+ (K+) level >=3.5 and \< 5.0 millimole per liter (mmol/L) at screening.

Exclusion criteria

Exclusion Criteria:

  • Mean seated diastolic blood pressure (DBP) on AOBPM >=110 mmHg at randomization.
  • Prior treatment (within the 4 weeks before screening) with angiotensin receptor Blocker (ARBs) and angiotensin converting enzyme inhibitor (ACEIs) (both taken simultaneously).
  • Serum sodium (Na+) level \< 135 millimole per liter (mmol/L) at screening, determined as per central laboratory.
  • functional heart failure (HF) Class IV at screening.
  • Planned percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary intervention/coronary artery bypass grafting done within 6 months prior to screening.
  • Uncontrolled diabetes with (HbA1c) > 10.0% (86 mmol/mol) at screening.
  • Fridericia's (QTcF) value > 470 milliseconds (ms) at screening, unless having a pacemaker.
  • Heart rate \< 45 or > 110 beats/min in a resting position, as per vital signs assessment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Arm 1: Baxdrostat 2 mg

    Participants will receive baxdrostat 2 mg tablet orally once daily.

    Drug: Baxdrostat

  • Placebo comparator
    Arm 2: Placebo

    Participants will receive placebo tablet orally once daily.

    Drug: Placebo

Interventions

  • Baxdrostat will be administered orally once daily.

    Also known as: RO6836191,, CIN-107

  • DrugPlacebo

    Placebo will be administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test

    The primary endpoint is individual participant's cortisol levels at each timepoint. Number of participants with normal stimulated serum total cortisol level at baseline are presented here. Characterisation of the serum total cortisol levels before and after ACTH stimulation test. An ACTH stimulation test using 250 μg ACTH was performed at baseline and Week 8 (End of Treatment), with serum cortisol level measured before and after ACTH stimulation test. Normal cortisol levels are defined as at least 18 μg/dL when measured 60 minutes (±10 minutes) after stimulation. If the Week 8 results show abnormal levels, a repeat test is conducted. In this repeat test, cortisol is considered abnormal only if both of the following conditions are met: the level is less than 14.8 μg/dL at 30 minutes (± 5 minutes) and less than 18 μg/dL at 60 minutes (±10 minutes).

    Time frame: Week 8

Secondary outcomes

  1. Incidence of Abnormal Stimulated Cortisol at Week 8

    The secondary endpoint is the incidence of abnormal stimulated cortisol after ACTH stimulation test at Week 8. Incidence of normal stimulated serum total cortisol level at baseline are presented. Normal cortisol levels are defined as at least 18 μg/dL when measured 60 minutes (±10 minutes) after stimulation. If the Week 8 results show abnormal levels, a repeat test is conducted. In this repeat test, cortisol is considered abnormal only if both of the following conditions are met: the level is less than 14.8 μg/dL at 30 minutes (± 5 minutes) and less than 18 μg/dL at 60 minutes (±10 minutes). Participants who had abnormal cortisol levels at the start of the study (baseline) were not included in this analysis.

    Time frame: Week 8

  2. Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

    Safety and tolerability of baxdrostat as compared with placebo was assessed. For this clinical study, AESIs include the following: hyperkalaemia, hyponatraemia and hypotension events that require medical intervention.

    Time frame: From Day 1 up to Week 8 or Safety follow-up (14 days post last dose), which ever comes first (up to 10 weeks)

07

Results

Posted Dec 17, 2025

Participant flow

This study was conducted in 10 sites in the United States of America from 10-June-2024 to 04-Dec-2024. The analyses presented in this report are based on a clinical data cutoff date of 28 January 2025.

Participant flow — Overall Study
MilestoneBaxdrostat 2 mgPlacebo
Started3216
Completed3016
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow up10

Outcome measures

SecondaryIncidence of Abnormal Stimulated Cortisol at Week 8

The secondary endpoint is the incidence of abnormal stimulated cortisol after ACTH stimulation test at Week 8. Incidence of normal stimulated serum total cortisol level at baseline are presented. Normal cortisol levels are defined as at least 18 μg/dL when measured 60 minutes (±10 minutes) after stimulation. If the Week 8 results show abnormal levels, a repeat test is conducted. In this repeat test, cortisol is considered abnormal only if both of the following conditions are met: the level is less than 14.8 μg/dL at 30 minutes (± 5 minutes) and less than 18 μg/dL at 60 minutes (±10 minutes). Participants who had abnormal cortisol levels at the start of the study (baseline) were not included in this analysis.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Incidence of Abnormal Stimulated Cortisol at Week 8
ParticipantsBaxdrostat 2 mgPlacebo
Abnormal Stimulated cortisol at Week 800
Normal Stimulated cortisol at Week 82615
SecondaryNumber of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

Safety and tolerability of baxdrostat as compared with placebo was assessed. For this clinical study, AESIs include the following: hyperkalaemia, hyponatraemia and hypotension events that require medical intervention.

Time frame:
From Day 1 up to Week 8 or Safety follow-up (14 days post last dose), which ever comes first (up to 10 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
ParticipantsBaxdrostat 2 mgPlacebo
Any AE106
Any SAE00
Any SAE with outcome death00
Any AE leading to discontinuation of IP10
Any possibly related AE63
Any possibly related SAE00
Any AESIs10
PrimaryNumber of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test

The primary endpoint is individual participant's cortisol levels at each timepoint. Number of participants with normal stimulated serum total cortisol level at baseline are presented here. Characterisation of the serum total cortisol levels before and after ACTH stimulation test. An ACTH stimulation test using 250 μg ACTH was performed at baseline and Week 8 (End of Treatment), with serum cortisol level measured before and after ACTH stimulation test. Normal cortisol levels are defined as at least 18 μg/dL when measured 60 minutes (±10 minutes) after stimulation. If the Week 8 results show abnormal levels, a repeat test is conducted. In this repeat test, cortisol is considered abnormal only if both of the following conditions are met: the level is less than 14.8 μg/dL at 30 minutes (± 5 minutes) and less than 18 μg/dL at 60 minutes (±10 minutes).

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test
ParticipantsBaxdrostat 2 mgPlacebo
Abnormal Stimulated cortisol at Week 800
Normal Stimulated cortisol at Week 82615

Adverse events

Collected over From Day 1 up to Week 8 or Safety follow-up (14 days post last dose), which ever comes first (up to 10 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baxdrostat 2 mg0/32 (0%)0/32 (0%)6/32 (18.8%)
Placebo0/16 (0%)0/16 (0%)6/16 (37.5%)
Most frequent other events
Most frequent other events
EventBaxdrostat 2 mgPlacebo
HeadacheNervous system disorders1/322/16
NasopharyngitisInfections and infestations0/321/16
Seasonal allergyImmune system disorders0/321/16
DizzinessNervous system disorders2/321/16
LethargyNervous system disorders1/321/16
Vision blurredEye disorders0/321/16
HypotensionVascular disorders1/321/16
NauseaGastrointestinal disorders2/320/16
VomitingGastrointestinal disorders2/320/16
Arthropod biteInjury, poisoning and procedural complications0/321/16

Baseline characteristics

The full analysis set included all randomized participants who received at least one dose of study intervention.

Age, Continuous
Age, Continuous(Years)Baxdrostat 2 mgPlaceboTotal
Mean64.1 ± 9.266.1 ± 7.464.8 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Baxdrostat 2 mgPlaceboTotal
Female17926
Male15722
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Baxdrostat 2 mgPlaceboTotal
Black or African American12719
White20929
08

Study locations

10 sites
  • Research Site
    Phoenix, Arizona 85018, United States
  • Research Site
    Tempe, Arizona 85281, United States
  • Research Site
    Montclair, California 91763, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2024, 5 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 5 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 28, 2024
StartActual
Jun 10, 2024
Primary completionActual
Dec 4, 2024
CompletionActual
Dec 4, 2024
Results first posted
Dec 17, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06336356
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Jun 10, 2024
Primary completion
Dec 4, 2024
Completion
Dec 4, 2024
Results posted
Dec 17, 2025
Last update
Dec 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion